A novel prognostic tool can be used to accurately identify adolescents at risk for initiating cigarette smoking.
These findings are consistent with emerging neurocognitive models linking interoception to emotion regulation and related health outcomes, providing valuable input in improving substance use disorder treatment.
Stigmatizing attitudes toward those who use opioids are associated with lower support for two evidence-based opioid harm reduction strategies.
Non-research industry payments to physicians may be associated with increases in opioid prescribing rates.
Among married individuals, first alcohol use disorder registration in national medical registries is associated with an increased risk of first alcohol use disorder registration in the spouse.
Adolescents with anxiety, mood, neurodevelopmental, sleep, and nonopioid substance use disorders and most mental health treatments were significantly more likely to receive opioids.
The new guideline focuses on evidence-based pharmacologic treatments in alcohol use disorder and includes recommendations about naltrexone, acamprosate, disulfiram, topiramate, and gabapentin.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- FDA to Ban Most Flavored Electronic Cigarettes
- Predictors of CBT Outcomes Identified in Youths With Anxiety Disorders
- Happy Childhood Memories Associated With Better Health
- FDA Launches MyStudies Mobile App in Effort to Increase Access to Real World Patient Data
- Heart Rate Variability Predicts Treatment Response in Anxious Depression